Lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer
Authors:
- 2 November 2022
- journal article
- research article
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 22 (11) , 1163-1175
Abstract
177Lu-vipivotide tetraxetan is a radiopharmaceutical that selectively targets prostate-specific membrane antigen (PSMA) and delivers beta-radiations to kill prostate cancer cells.Extensive experien...Keywords
Funding Information
- funding
This publication has 84 references indexed in Scilit:
- Enzalutamide in Castration-resistant Prostate Cancer Patients Progressing After Docetaxel and AbirateroneEuropean Urology, 2014
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2013
- Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamideAnnals of Oncology, 2013
- Increased Survival with Enzalutamide in Prostate Cancer after ChemotherapyNew England Journal of Medicine, 2012
- Theranostics: Combining Imaging and TherapyBioconjugate Chemistry, 2011
- Abiraterone and Increased Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2011
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trialThe Lancet, 2010
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerNew England Journal of Medicine, 2010
- Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 StudyJournal of Clinical Oncology, 2008
- Phase III Study of Mitoxantrone Plus Low Dose Prednisone Versus Low Dose Prednisone Alone in Patients With Asymptomatic Hormone Refractory Prostate CancerJournal of Urology, 2002